Alteogen’s Hybrozyme™ technology is designed to enhance the flexibility and stability of protein structures while preserving the enzyme’s original mechanism of action.

By applying Hybrozyme™ technology to PH20, a type of human hyaluronidase, Alteogen has developed a new human hyaluronidase with improved enzymatic activity and thermal stability. This enzyme hydrolyzes hyaluronic acid in subcutaneous tissue, enabling a shift from intravenous (IV) to subcutaneous (SC) drug administration. As a result, injection time can be reduced from at least 30 minutes for intravenous infusion to under 5 minutes for subcutaneous injection, greatly improving patient convenience. In addition, this technology is used to facilitate the diffusion of anesthetics in ophthalmic surgery and to break down hyaluronic acid fillers injected into the skin in cosmetic procedures.

The new human hyaluronidase developed using Hybrozyme™ Technology shows higher protein expression in animal cells compared to wild-type PH20, allowing for greater production from the same raw materials. With enhanced enzymatic activity and thermal stability, it is effective at lower enzyme doses and offers a longer shelf life than existing products. Depending on the application, such as biosimilars or new drugs, hyaluronidases with different enzymatic activities can be selected and used.

*Technology licensed to global companies as a platform to enable subcutaneous formulations